Rituximab-induced vasculitis: A rare occurrence

Abstract

Rituximab is a chimeric murine/human monoclonal antibody that targets the CD20 antigen expressed on B lymphocytes. It is Food and Drug Administration-approved for use in pemphigus vulgaris (PV). Usual adverse effects are mild, and vasculitis has been reported very rarely. There are only three biopsy-proven case reports of rituximab-induced vasculitis in medical published literature and none in pemphigus. Here, we report a case of rituximab-induced vasculitis in a 46-year-old female with PV.